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rch 4, 2014.his study examined the impact of omentin on myocardial injury in a mouse model of ischemia/reperfusion (I/R)
and explored its underlying mechanisms.Background Obesity is a major risk factor for ischemic heart disease. Omentin is a circulating adipokine that is down-regulated
by obesity.Methods In patients who underwent successful reperfusion treatment after acute myocardial infarction, cardiac function and
perfusion defect were assessed by using scintigraphic images. Mice were subjected to myocardial ischemia followed
by reperfusion.Results This study found that high levels of plasma omentin were associated with improvement of heart damage and function
after reperfusion therapy in patients with acute myocardial infarction. Systemic administration of human omentin to
mice led to a reduction in myocardial infarct size and apoptosis after I/R, which was accompanied by enhanced
phosphorylation of AMP-activated protein kinase (AMPK) and Akt in the ischemic heart. Fat-speciﬁc overexpression
of human omentin also resulted in reduction of infarct size after I/R. Blockade of AMPK or Akt activity reversed
omentin-induced inhibition of myocardial ischemic damage and apoptosis in mice. In cultured cardiomyocytes,
omentin suppressed hypoxia/reoxygenation-induced apoptosis, which was blocked by inactivation of AMPK or Akt.Conclusions Our data indicate that omentin functions as an adipokine that ameliorates acute ischemic injury in the heart by
suppressing myocyte apoptosis through both AMPK- and Akt-dependent mechanisms. (J Am Coll Cardiol
2014;63:2722–33) ª 2014 by the American College of Cardiology FoundationIschemic heart disease, including myocardial infarction, is
the major cause of mortality worldwide (1). Although
complications of obesity are associated with the severity, Nagoya University Graduate School of Med-
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4; revised manuscript received March 3, 2014,and adverse outcome of ischemic heart disease (2–4), the
molecular mechanisms by which obesity contributes to the
development of heart diseases are incompletely understood.
Adipose tissue functions as an endocrine organ by secreting
various bioactive molecules, also referred to as adipokines,
which can directly affect the nearby or remote tissues (5).
Omentin/intelectin-1 has been identiﬁed as an adipokine
that is detected abundantly in human visceral fat tissue (6,7).
Plasma omentin levels are down-regulated in patients with
obesity-related disorders, including type 2 diabetes, meta-
bolic syndrome, and atherosclerosis (8–11). Furthermore,
low levels of circulating omentin are associated with the
prevalence of coronary heart disease in male patients
(12–14). Decreased levels of circulating omentin are also
associated with the presence and severity of coronary artery
disease in postmenopausal women (15). An experimental
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2723study found that omentin stimulates glucose uptake in
cultured adipocytes (6).
Omentin also reportedly enhances vasodilation in isolated
blood vessels and reduces inﬂammatory responses in cultured
endothelial cells (16,17). We have reported that administra-
tion of omentin promotes revascularization processes of
ischemic muscle (18). A recent report demonstrated that
exposure of cardiomyocytes to conditioned media derived
from epicardial adipose tissue from patients with type 2 dia-
betes leads to induction of contractile dysfunction and in-
sulin resistance, which is prevented by recombinant omentin
protein (19). Thus, it is plausible that omentin participates in
obesity-related metabolic and cardiovascular complications.
However, nothing is known about the role of omentin in
regulation of ischemic heart disease. In the present article, we
assessed the clinical signiﬁcance of omentin in acute
myocardial infarction (AMI) and investigated whether hu-
man omentin modulates acute ischemic injury in the heart
in vivo and in vitro.
Methods
For an expanded Methods section, please see the Online
Appendix.
Clinical study. A total of 20 patients with ST-segment–
elevated AMI of the left anterior descending coronary artery
alone that was treated successfully by coronary stenting (bare
metal stents) were enrolled in this study. Medication use
included 200 mg of ticlopidine, 160 to 200 mg of aspirin,
an angiotensin type I receptor antagonist, and statins. The
percutaneous coronary intervention was performed within
6 h from the onset of chest pain by experienced inter-
ventionists according to the guidelines for coronary angio-
graphy and percutaneous coronary intervention of the
American Heart Association. We excluded patients with
adverse cardiovascular events, including angiographic reste-
nosis during the observation period, major bleeding requiring
blood transfusion during the percutaneous coronary inter-
vention, a history of hepatic or renal dysfunction, malignant
neoplasia, and an unwillingness to participate. This protocol
was approved by the ethics committee of the Nagoya Uni-
versity Graduate School of Medicine (Nagoya, Japan), and
all subjects enrolled provided written informed consent.
At 7 days after AMI, all patients received an injection
of 111 MBq of iodine-123-beta-methyl iodophenyl pentade-
canoic acid (123I-BMIPP). The single-photon emission
computed tomography (SPECT) image acquisition for the
early BMIPP image began at 20 minutes after injection.
A second BMIPP SPECT acquisition was started at 3 h
after injection. At 6 months after AMI, patients also
received an injection of 147 MBq of 99mTc-tetrofosmin,
and SPECT images were then acquired within 2 h. These
scintigraphic examinations were used to evaluate myocardial
salvage index and ejection fraction. The myocardial salvage
index was calculated as [(percent initial perfusion defect
size – percent ﬁnal infarct size)/percent initial perfusiondefect size], as described previ-
ously (20). The initial perfusion
defect size was obtained by using
BMIPP SPECT imaging, and
the ﬁnal infarct size was obtained
by using tetrofosmin SPECT
imaging. Blood samples were
obtained in a fasting state at day
7 after AMI to determine plasma
omentin levels.
Mouse model of ischemia/reper-
fusion injury. Male and female
C57BL/6 mice were purchased
from Oriental BioService, Inc.
(Kyoto, Japan).We subjectedmice
at the age of 10 to 12 weeks
to myocardial ischemia/reperfu-
sion (I/R), as described previously
(21,22). Brieﬂy, after anesthe-
tization (pentobarbital 50 mg/kg
intraperitoneally) and intubation,
the left anterior descending artery
was ligated for 60 min with a su-
ture by using a snare occluder and
then loosened. At 24 h after
reperfusion, the suturewas re-tied,
and Evans blue dye was systemi-
cally injected into the mice to
determine the nonischemic tissue.
The heart was excised, cut, and incubated with 2,3,
5-triphenyltetrazolium chloride to determine the infarcted
region. Left ventricular area, the area at risk, and infarct area
were assessed by computerized planimetry using ImageJ soft-
ware. Adenoviral vector expressing human omentin (Ad-
omentin) or adenoviral vector expressing beta-galactosidase
(Ad-b-gal) were injected into the jugular vein of mice 3 days
before the I/R injury (4.0  107 PFU per mouse). In some
experiments, LY294002 (40 mg/kg) or compound C (20 mg/
kg) dissolved in dimethyl sulfoxide or dimethyl sulfoxide was
intraperitoneally injected into mice before the operation and
after reperfusion.
Our initial experiment demonstrated that plasma human
omentin was detected at the mean concentration of 274 
41.9 ng/ml at 30 min after intravenous injection of recom-
binant human omentin protein (0.1 mg/g per mouse).
Because this concentration of omentin in the bloodstream
was similar to the level of omentin that was observed in
healthy subjects (8,10,14), we injected recombinant human
omentin protein (0.1 mg/g per mouse) or vehicle (phosphate-
buffered saline) through the right jugular vein before the
induction of ischemia or 5 min after reperfusion. All pro-
tocols were approved by the Institutional Animal Care and
Use Committee of Nagoya University.
Generation of transgenic mice overexpressing human
omentin in a fat-speciﬁc manner. Omentin-transgenic
(OMT-TG) mice were generated by subcloning the
Table 1 Clinical Characteristics (N ¼ 20)
Age, yrs 62.5  1.6
Male/female 13/7
Body mass index, kg/m2 24.3  0.64
Systolic blood pressure, mm Hg 116.4  2.1
Glucose, mg/dl 115.5  6.1
LDL cholesterol, mg/dl 123.8  7.9
HDL cholesterol, mg/dl 46.3  4.1
Triglyceride, mg/dl 104  8.1
Peak creatine phosphokinase, IU/ml 112.5  8.6
Omentin, ng/ml 241.5  27.0
123I-BMIPP
Initial perfusion defect size, % 39.1  2.0
EF in acute phase, % 43.7  1.6
99mTC-TF
Final infarct size, % 15.8  1.6
EF in chronic phase, % 56.7  2.2
Myocardial salvage index 0.59  0.03
Changes in EF 13.1  2.0
Values are n or mean  SEM.
123I-BMIPP ¼ iodine-123-beta-methyl iodophenyl pentadecanoic acid; 99mTC-TF ¼ technetium-
99m-tetrofosmin; EF ¼ ejection fraction; HDL ¼ high-density lipoprotein; LDL ¼ low-density
lipoprotein.
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2724full-length human omentin complementary deoxy-
ribonucleic acid into pBluescript (Stratagene, La Jolla,
California) vector with the 5.4 kb murine aP2 promoter. The
deoxyribonucleic acid fragment containing aP2 gene pro-
moter, the human omentin, and polyadenylation sequences
were excised with ClaI and SacII restriction enzymes and
used for pronuclear microinjection. OMT-TG mice in a
C57BL/6J genetic background were generated by Oriental
BioService. OMT-TG founders were determined by poly-
merase chain reaction analysis and bred to C57BL/6J mice to
generate stable lines.
Statistical analysis. Data are presented as mean  SEM.
The Student t test was performed for comparison between 2
independent groups. The one-way analysis of variance testFigure 1 Association of Plasma Omentin Levels at 7 Days After AMI
Association of plasma omentin levels at 7 days after acute myocardial infarction (AMI) w
A total of 20 patients who underwent successful reperfusion treatment after AMI were enwas performed for comparison of 3 or more independent
groups. The Fisher protected least signiﬁcant difference test
was used only if the overall comparison by one-way analysis
of variance test was statistically signiﬁcant. All continuous
variables were assumed to be normally distributed. The
correlations between omentin levels and the indicated pa-
rameters were examined by using single logistic regression
analyses. A value of p < 0.05 denoted the presence of a
statistically signiﬁcant difference.Results
Association of omentin with myocardial salvage and
function in patients with myocardial infarction. First, we
examined whether the circulating omentin level is associated
with myocardial function and injury in patients with AMI.
A total of 20 patients who underwent successful reperfusion
treatment after AMI were enrolled (Table 1). Cardiac
function and perfusion defect were assessed by using scin-
tigraphic images of 123I-BMIPP in the acute phase and
99mTc-tetrofosmin in the chronic phase. Plasma omentin
levels at 7 days’ post-AMI were positively associated with
myocardial salvage index, representing the proportion of
initial perfusion defect rescued by reperfusion and recovery
of ejection fraction in the chronic phase (Figs. 1A and 1B).
Systemic delivery of adenoviral vectors encoding human
omentin reduces myocardial infarct size and apoptosis in
mice after I/R. To test whether increased production of
circulating omentin affects acute cardiac ischemic injury in
mice, male wild-type C57BL/6J mice were intravenously
treated with Ad-omentin or Ad-b-gal as a control, followed
by subjection to 60 min of myocardial ischemia and 24 h of
reperfusion. Murine omentin messenger ribonucleic acid in
heart and adipose tissue of wild-type mice after the surgical
induction of I/R could not be detected (data not shown).
Although circulating human omentin could not be detected
in the control wild-type mice, mean plasma human omentinWith Myocardial Salvage Index and Changes in EF
ith (A) myocardial salvage index and (B) changes in ejection fraction (EF).
rolled. Values are mean  SEM.
Figure 2 Systemic Delivery of Omentin Improves Myocardial Ischemic Injury in Mice
(A) Adenovirus-mediated administration of omentin reduces infarct size after myocardial ischemia/reperfusion (I/R). Wild-type mice were systemically treated with an adenoviral
vector expressing human omentin (Ad-omentin) or adenoviral vector expressing beta-galactosidase (Ad-b-gal) as control (4.0  107 PFU total) and subjected to I/R injury.
Representative pictures of the heart sections stained with Evans blue dye and 2,3,5-triphenyltetrazolium chloride at 24 h after I/R are shown in the upper panels. Left ventricular
(LV) area, the area at risk (AAR) (red), and infarct area (IA) (white) were measured. Quantitative analysis of infarct size is shown in the lower panel (n ¼ 6 in each group). (B) Ad-
omentin treatment reduced plasma creatine phosphokinase at 24 h after reperfusion (n ¼ 6 in each group). (C) Ad-omentin reduced myocyte apoptosis in ischemic heart in
mice. Representative photographs of heart sections stained with deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) (green), sarcomeric actinin (red), and
40,6-diamidino-2-phenylindole (DAPI) (blue) are shown in the upper panels. Quantitative analyses of TUNEL-positive myocytes are shown in the lower panel (n¼ 6 in each group).
(D) Omentin attenuated apoptosis of cultured cardiac myocytes. Neonatal rat cardiac myocytes were treated with omentin protein (300 ng/ml) or vehicle under conditions of
normoxia or hypoxia/reoxygenation (H/R). Upper panels show representative photographs of cardiac myocytes stained with TUNEL (green) and DAPI (blue). Lower panel shows
quantitative analysis of TUNEL-positive cells (n ¼ 8 in each group). (E) Omentin inhibited the degree of cleaved caspase-3 of cardiac myocytes under conditions of H/R (n ¼ 4 in
each group).
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2725levels increased to 555.9  141.7 ng/ml in Ad-omentin–
treated wild-type mice at 5 days after adenoviral injection.
All mice survived after the surgical induction of I/R. Body
weight and blood pressure did not differ between the 2
experimental groups (data not shown).
Figure 2A shows representative photographs of heart
tissues stained with Evans blue dye to delineate the area atrisk and 2,3,5-triphenyl tetrazolium chloride to delineate the
infarct area. Systemic delivery of Ad-omentin signiﬁcantly
reduced the mean infarct area/area at risk and infarct area/
left ventricular ratios by 53.9  7.1% and 51.5  9.6%,
respectively, compared with control mice. In contrast, the
area at risk/left ventricular ratio did not differ between the
2 experimental groups. Furthermore, circulating levels of
Figure 3 Omentin Enhances Phosphorylation of AMPK and Akt in the Ischemic Heart and Cardiac Myocytes
(A) AMP-activated protein kinase (AMPK) and Akt phosphorylation in the ischemic heart of mice treated with Ad-omentin or Ad-b-gal at 24 h after sham or I/R surgery. Wild-type
mice were systemically treated with Ad-omentin or Ad-b-gal as control (4.0 107 PFU total) followed by subjection to I/R injury. Phosphorylation of AMPK (P-AMPK) and Akt (P-Akt)
was determined according to Western blot analysis. (B) Time-dependent changes in P-AMPK and P-Akt in cardiac myocytes after stimulation with omentin (300 ng/ml) as
assessed by using Western blotting. The phosphorylation level was determined by measurement of the corresponding band intensities by using ImageJ software, and the relative
values were expressed relative to alpha-tubulin signals. Values are mean  SEM (n ¼ 5). ACC ¼ acetyl-CoA carboxylase; other abbreviations as in Figure 2.
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2726creatine phosphokinase, a marker of heart injury, were
signiﬁcantly lower in Ad-omentin–treated mice compared
with control mice at 24 h after reperfusion (Fig. 2B). In
addition, we subjected female wild-type C57BL/6J mice to
myocardial ischemia followed by reperfusion. Systemic
administration of Ad-omentin to female mice signiﬁcantly
reduced myocardial infarct size (Online Fig. 1). Thus,
omentin could improve acute ischemic injury in the heart
regardless of sex.
To investigate the impact of omentin on myocyte
apoptosis in the heart, we stained heart sections with
deoxynucleotidyl transferase–mediated dUTP nick end la-
beling (TUNEL) and sarcomeric actinin at 24 h after I/R or
sham operation. Figure 2C shows representative ﬂuorescent
photographs of TUNEL-positive nuclei in the area at risk.
Quantitative analysis revealed that Ad-omentin signiﬁcantly
reduced the frequencies of TUNEL-positive myocytes in
the ischemic heart compared with controls. In contrast,
little or no TUNEL-positive myocytes were observed in the
heart of control or omentin-treated mice after the sham
operation.To examine the effect of omentin on apoptosis at a
cellular level, neonatal rat cardiac myocytes were subjected
to normoxia or hypoxia/reoxygenation under conditions of
serum deprivation in the presence of recombinant human
omentin protein or vehicle. Treatment with a physiological
concentration of omentin protein signiﬁcantly suppressed
the frequencies of TUNEL-positive cells under condi-
tions of normoxia and hypoxia/reoxygenation (Fig. 2D).
Furthermore, the induction in cleaved caspase-3 expression
in response to hypoxia/reoxygenation in cardiac myocytes
was suppressed by omentin treatment (Fig. 2E).
Omentin activates AMP-activated protein kinase and
Akt in the ischemic heart and cardiac myocytes. Because
AMP-activated protein kinase (AMPK) and Akt reportedly
protect myocytes from apoptosis and ischemic injury
(21,23–26), we assessed the activating phosphorylation of
AMPK at Thr-172 and Akt at Thr-308 in the heart after
the sham or I/R operation. I/R led to an increase in
phosphorylation of AMPK and Akt in the control heart,
but this induction was enhanced in the heart of Ad-
omentin–treated mice (Fig. 3A). We next assessed the
Figure 4 AMPK Is Involved in the Suppressive Actions of Omentin of Myocardial Infarct Size and Apoptosis
Effect of AMPK inhibition on (A) omentin-induced phosphorylation signals and (B) survival of cardiac myocytes. Cardiac myocytes were transduced with an adenoviral vector
encoding c-Myc–tagged dominant-negative AMPK (Ad-dnAMPK) or Ad-b-gal for 24 h. Cardiac myocytes were treated with omentin (300 ng/ml) or vehicle for 60 min, and phos-
phorylation of acetyl-CoA carboxylase (P-ACC) and P-Akt was analyzed by using Western blotting. After transduction with adenoviral vectors, cardiac myocytes were cultured in the
presence of omentin (300 ng/ml) or vehicle under conditions of H/R, and TUNEL-positive nuclei were quantiﬁed (n ¼ 4 in each group). Blockade of AMPK activation reversed the
effects of omentin on (C) P-ACC, (D)myocardial infarct size, and (E) apoptosis in mice after I/R. After systemic administration of Ad-omentin or Ad-b-gal (4.0 107 PFU total), wild-
type mice were intraperitoneally treated with AMPK inhibitor compound C (20 mg/kg) dissolved in dimethyl sulfoxide or vehicle (dimethyl sulfoxide) from 1 day before I/R until the
mice were killed. P-ACC and P-Akt was determined by using Western blot analysis. Quantitative analyses of the AAR/LV, the IA/AAR, and the IA/LV ratios are shown (n¼ 6 in each
group). Quantitative analyses of TUNEL-positive myocytes are shown (n ¼ 5 in each group). Values are mean  SEM. Abbreviations as in Figures 2 and 3.
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2727phosphorylation of AMPK and Akt in cardiac myocytes
after treatment with human omentin protein or vehicle.
Omentin stimulated the phosphorylation of AMPK in a
time-dependent manner, with maximal levels occurring at
60 min (Fig. 3B). Similarly, omentin time-dependently
enhanced the phosphorylation of acetyl-CoA carboxylase,
a downstream target of AMPK in cardiac myocytes.
Omentin also promoted Akt phosphorylation in a time-
dependent manner, with maximal induction at 120 min.
AMPK participates in the suppressive effects of omentin
on myocardial injury. To test whether AMPK signaling is
involved in the antiapoptotic actions of omentin, cultured
cardiac myocytes were transduced with c-Myc–taggeddominant-negative mutant of AMPK (Ad-dnAMPK) or
Ad-b-gal as a control. Transduction with Ad-dnAMPK
suppressed omentin-stimulated phosphorylation of acetyl-
CoA carboxylase in cardiac myocytes (Fig. 4A). In
contrast, Ad-dnAMPK did not affect Akt phosphorylation
in response to omentin. Furthermore, transduction with
Ad-dnAMPK reversed the inhibitory effects of omentin
on apoptosis under conditions of hypoxia/reoxygenation
(Fig. 4B).
To further examine whether AMPK is involved in
omentin-mediated protection against I/R damage in vivo,
we intraperitoneally injected AMPK inhibitor compound
C or vehicle into mice. Administration of compound C
Figure 5 Akt Signaling Contributes to the Protective Actions of Omentin on Myocardial Injury
Effect of Akt inactivation on (A) omentin-stimulated phosphorylation signals and (B) survival of cardiac myocytes. Cardiac myocytes were transduced with an adenoviral
vector producing hemagglutinin-tagged dominant-negative Akt (Ad-dnAkt) or Ad-b-gal for 24 h. Cells were treated with omentin (300 ng/ml) or vehicle for 60 min for
determination of phosphorylation of glycogen synthase kinase–3 (P-GSK-3) and P-AMPK. TUNEL-positive nuclei were quantiﬁed after treatment of myocytes with omentin
(300 ng/ml) or vehicle under conditions of H/R (n ¼ 4 in each group). Effect of PI3-kinase inhibitor on (C) phosphorylation signals, (D), infarct size and (E) apoptosis in
response to I/R after systemic administration of omentin. After systemic delivery of Ad-omentin or Ad-b-gal (4.0  107 PFU total), wild-type mice were intraperitoneally
treated with PI3-kinase inhibitor LY294002 (40 mg/kg) dissolved in dimethyl sulfoxide or vehicle (dimethyl sulfoxide) from 1 day before I/R until the mice were killed.
Quantitative analyses of infarct size (AAR/LV, IA/AAR, and IA/LV ratios) (n ¼ 6 in each group) and TUNEL-positive myocytes (n ¼ 5 in each group) are shown. Involvement of
integrin anb3 in omentin-stimulated (F) P-Akt and (G) survival of cardiac myocytes. Cardiac myocytes were pre-treated with anti-integrin anb3 antibody (25 mg/ml) or control
immunoglobulin G (IgG) (25 mg/ml) for 60 min. Cells were treated with omentin (300 ng/ml) or vehicle for 60 min. P-Akt and P-AMPK were determined by using Western blot
analysis. TUNEL-positive myocytes in response to H/R were quantiﬁed after treatment with omentin (300 ng/ml) or vehicle (n ¼ 5 in each group). Values are mean  SEM.
Abbreviations as in Figures 2 and 4.
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2728reduced the omentin-induced increase in acetyl-CoA
carboxylase phosphorylation in the ischemic heart
without altering the Akt phosphorylation (Fig. 4C).
Although compound C had no effects on myocardial
infarct size in control-treated mice, it signiﬁcantly blocked
the inhibitory actions of omentin on myocardial infarct
area of mice after I/R (Fig. 4D). Compound C also
reversed the omentin-induced decrease in TUNEL-positive myocytes in the ischemic heart (Fig. 4E). Thus,
omentin can reduce myocardial infarct size and apoptosis
in response to I/R injury partly via an AMPK-mediated
signaling pathway.
Akt is involved in the inhibitory effects of omentin on
cardiac ischemic injury. To assess whether Akt activation
participates in the antiapoptotic effects of omentin, cardiac
myocytes were transduced with hemagglutinin-tagged
Figure 6 One-Shot Administration of Exogenous Omentin Attenuates Myocardial Ischemic Damage in Mice
Effect of systemic delivery of omentin protein on (A)myocardial infarct size and (B) apoptosis in mice in response to I/R. Wild-type mice were treated with human omentin protein
(0.1 mg/g per mouse) or vehicle at 5 min before ischemic induction. Infarct size in the heart was quantiﬁed (n¼ 6 in each group). Heart sections were stained with TUNEL (green),
sarcomeric actinin (red), and DAPI (blue), and TUNEL-positive cells were quantiﬁed (n¼ 5 in each group). (C) Administration of omentin protein after ischemic injury reduced infarct
size inmice.Wild-typemicewere treatedwith human omentin protein (0.1 mg/g permouse) or vehicle at 5min after reperfusion. Infarct size in the heart was quantiﬁed (n¼6 in each
group). Value aremeanSEM. (D) P-AMPKand P-Akt in the heart ofmice after I/R that had received omentin protein or vehicle either 5min before the induction of ischemia or 5min
after reperfusion (n ¼ 6 in each group). P-AMPK and P-Akt was determined by using Western blot analysis. Abbreviations as in Figures 2 and 3.
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2729dominant-negative mutant of Akt (Ad-dnAkt) or control
Ad-b-gal. Transduction with Ad-dnAkt suppressed
omentin-induced phosphorylation of glycogen synthase
kinase–3, a downstream target of Akt in cardiac myocytes
(Fig. 5A). However, Ad-dnAkt treatment had no effects on
AMPK phosphorylation after omentin stimulation. More-
over, Ad-dnAkt canceled the omentin-mediated inhibition
of myocyte apoptosis in response to hypoxia/reoxygenation
(Fig. 5B).
To investigate whether Akt signaling mediates omentin-
induced protection from cardiac ischemic injury in vivo, we
intraperitoneally injected PI3-kinase inhibitor LY294002
or vehicle into mice. Administration of LY294002 di-
minished omentin-induced phosphorylation of glycogen
synthase kinase–3 in the ischemic heart without inﬂu-
encing AMPK phosphorylation (Fig. 5C). AlthoughLY294002 did not affect myocardial infarct size and
apoptosis in control-treated mice, it reversed the suppres-
sive actions of omentin on infarct size and myocyte
apoptosis after myocardial I/R (Figs. 5D and 5E). Thus,
omentin attenuates myocardial I/R injury partly through
activation of Akt signaling that is independent of AMPK.
Furthermore, it is unlikely that AMPK and Akt mutually
affect each other’s response to omentin in ischemic heart
and cardiac myocytes.
Integrin anb3 is one of the major integrins that are
expressed in cardiac myocytes (27), and it activates Akt-
dependent survival pathways in various cells (28). To
determine whether integrin anb3 is involved in omentin-
stimulated Akt activation in vitro, cardiac myocytes were
preincubated with a neutralizing antibody against integrin
anb3 or control immunoglobulin G followed by treatment
Figure 7
Overproduction of Fat-Derived Omentin Protects the
Heart From Myocardial Ischemic Damage
(A) Restrictive expression of human omentin gene in fat tissue of human omentin
transgenic (OMT-TG) mice. Transcript expression of human omentin in various
tissues of OMT-TG mice was determined by real-time polymerase chain reaction
methods (n ¼ 4). Fat-speciﬁc OMT-TG mice show a reduction in (B) infarct size and
(C) apoptosis after myocardial I/R. Representative pictures of heart tissues from
OMT-TG and control mice are shown in the upper panels. Quantitative analysis of
infarct size is shown in the lower panel (n ¼ 5 in each group). Heart sections were
stained with TUNEL (green), sarcomeric actinin (red), and DAPI (blue), and TUNEL-
positive cells were quantiﬁed (n ¼ 5 in each group). Results are shown as mean 
SEM. Epi ¼ epididymal adipose tissue; ND ¼ not detectable; Sub ¼ subcutaneous
adipose tissue; other abbreviations as in Figure 2.
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2730with omentin or vehicle. Pretreatment with anti-integrin
anb3 antibody suppressed the omentin-induced increase in
Akt phosphorylation, whereas it did not affect omentin-
induced AMPK activation (Fig. 5F). Pre-treatment with
anti-integrin anb3 antibody also reversed the inhibitory
effects of omentin on apoptotic response to hypoxia/reox-
ygenation (Fig. 5G). In contrast, pre-treatment with anti-
integrin anb5 antibody did not affect omentin-induced Akt
activation and survival of cardiac myocytes (data not shown).
These data suggest that omentin suppresses apoptosis partly
through an integrin anb3-Akt–mediated pathway that is
independent of AMPK.
Omentin modulates the phosphorylation of endothelial
nitric oxide synthase and nuclear factor–kB in ischemic
heart. The key regulator of endothelial function, endo-
thelial nitric oxide synthase, protects myocytes from I/R
injury (29,30), and the inﬂammatory mediator nuclear
factor (NF)-kB contributes to myocardial injury after I/R
(31,32). Therefore, we assessed the effect of omentin on
phosphorylation status of endothelial nitric oxide synthase
and NF-kB in the heart after the sham or I/R operation.
I/R led to an increase in phosphorylation of endothelial
nitric oxide synthase in the control heart, but this in-
duction was enhanced in the heart of omentin-treated
mice (Online Fig. 2). Phosphorylation of NF-kB in
myocardium was increased in response to I/R, but the
increase in NF-kB phosphorylation was suppressed by
omentin treatment.
Recombinant omentin protein minimizes myocardial
infarct size in mice after I/R. To test whether systemic
administration of omentin protein could minimize infarct
area before or after myocardial ischemia, we intravenously
injected a single dose of recombinant human omentin pro-
tein or vehicle to wild-type mice 5 min before the induction
of ischemia or 5 min after reperfusion. Plasma glucose and
insulin levels at 24 h after reperfusion did not differ between
the 4 experimental groups (data not shown). Systemic
administration of omentin protein to mice, before ischemia,
signiﬁcantly attenuated infarct size after I/R relative to
control mice (Fig. 6A). Administration of omentin protein
before ischemia reduced the frequencies of apoptotic myo-
cytes in the ischemic heart compared with control hearts
(Fig. 6B). Systemic delivery of omentin protein after
reperfusion also led to a signiﬁcant reduction in myocardial
infarct size in mice after I/R (Fig. 6C). In addition, we
assessed the phosphorylation of AMPK and Akt in the heart
of mice after I/R that had received omentin protein or
vehicle either 5 min before the induction of ischemia or 5
min after reperfusion. Omentin administration, either before
ischemia or after reperfusion, led to increases in AMPK and
Akt phosphorylation in the ischemic heart (Fig. 6D).
Fat-speciﬁc OMT-TG mice are protected from
myocardial I/R injury. Although human omentin is
abundantly detected in visceral fat tissue, murine omentin
transcript is expressed exclusively in the small intestine
(33). Thus, to test whether fat-derived omentin could
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2731minimize myocardial infarct size, we generated transgenic
mice expressing the human omentin gene under the con-
trol of the aP2 promoter (fat-speciﬁc OMT-TG mice) in
the background of C57BL/6J. Human omentin transcript
was speciﬁcally expressed in subcutaneous fat and epidid-
ymal fat but not in other tissues examined in OMT-TG
mice at 9 weeks of age (Fig. 7A). Plasma human
omentin levels increased to 1,293.1  207.9 ng/ml in
OMT-TG mice, whereas human omentin protein was
undetectable in littermate control mice. Morphometric and
hemodynamic parameters of fat-speciﬁc OMT-TG mice
seemed indistinguishable from littermate mice under basal/
physiological conditions (Online Table 1). Of note,
fat-speciﬁc OMT-TG mice showed a marked reduction in
mean infarct area/area at risk and infarct area/left ven-
tricular ratios by 56.8  7.9% and 57.8  9.9%, respec-
tively, compared with control mice (Fig. 7B). OMT-TG
mice also exhibited a lower frequency of apoptotic myo-
cytes in the ischemic heart compared with control mice
(Fig. 7C). In contrast, little or no TUNEL-positive
myocytes were observed in the heart of control or OMT-
TG mice after the sham operation.
Discussion
The present study provides the ﬁrst evidence that the adipo-
kine omentin confers resistance to acute ischemic damage in
the heart. Clinically, increased levels of plasma omentin in
post-AMI patients were associated with improvement in
myocardial damage and function after successful reperfusion
therapy. Increase in circulating human omentin by adenoviral
or transgenic overexpression systems before the induction of
ischemia led to a reduction in cardiac injury after reperfusion in
mice. Supplementation of exogenous human omentin protein,
either before ischemia or after reperfusion, was also effective in
limiting the myocardial I/R damage in mice. Thus, these data
suggest that the therapeutic approaches to enhance circulating
omentin levels before or after ischemic insult can be valuable
for prevention or treatment of acute myocardial injury.
Myocyte apoptosis is a key feature in various heart dis-
orders (34,35). A limitation of apoptosis represents an
important therapeutic target for ischemic heart disease
(36,37). In the present study, omentin attenuated myocyte
apoptosis in response to I/R in a murine model. Omentin
also suppressed stress-inducible cardiomyocyte apoptosis
in vitro. Similarly, omentin reportedly suppresses apoptosis
of endothelial cells under conditions of serum starvation
(18). Therefore, the ability of omentin to attenuate
myocardial infarct size after I/R is dependent, at least in part,
on its ability to reduce apoptosis in the heart.
It has been shown that both AMPK and Akt function as
signaling molecules that regulate cellular apoptosis and
survival (21,24,25,38). We have demonstrated that omentin
stimulates the phosphorylation of AMPK or Akt in cultured
endothelial cells (17,18). Consistent with these ﬁndings,
omentin promoted activation of AMPK and Akt in culturedmyocytes and ischemic hearts of mice. Importantly, inhibi-
tion of AMPK activity blocked the suppressive effects of
omentin on cardiac injury and myocyte apoptosis in an Akt-
independent manner. Blockade of Akt activity reversed
omentin-induced inhibition of myocardial ischemic damage
and apoptosis independently of AMPK signaling. Further-
more, integrin anb3 seemed to participate in omentin-
inducible Akt survival signaling that was independent of
AMPK activation. Taken together, these data suggest that
omentin protects the heart from ischemic injury through its
ability to promote 2 independent pro-survival pathways
involving AMPK and Akt within cardiac myocytes.
We have shown previously that omentin enhances the
activating phosphorylation of endothelial nitric oxide syn-
thase in both ischemic muscles and cultured endothelial cells
(18). Omentin also promotes vasodilation of isolated aorta,
which is prevented by nitric oxide synthase inhibition (16).
In addition, omentin reduces tumor necrosis factor-alpha–
stimulated expression of adhesion molecules in endothelial
cells via suppression of the NF-kB pathway (39). In
agreement with these ﬁndings, the present study found that
treatment of mice with omentin led to enhancement of
endothelial nitric oxide synthase phosphorylation and sup-
pression of NF-kB phosphorylation in the ischemic heart.
Collectively, omentin can modulate endothelial function
and inﬂammatory response in the heart in addition to its
pro-survival properties, thereby contributing to protection
against the myocardial ischemic injury.
Omentin was originally identiﬁed as a soluble
galactofuranose-binding lectin (7). It has been shown that
differential saccharide-binding speciﬁcities are observed be-
tween human and mouse omentin (40). In this context, hu-
man omentin forms a disulﬁde-linked and N-glycosylated
trimer, whereas mouse homologue is present in a monomeric
form. It has been reported that murine omentin is speciﬁcally
expressed in the small intestine despite the abundant expres-
sion of human omentin in visceral fat depots (6,7,33). Thus, it
is possible that human omentin has a distinct function from
murine homologue in the setting of cardiovascular disease.
Our present study found that transgenic overexpression of
human omentin in a fat-speciﬁc manner effectively prevented
myocardial ischemic damage and apoptosis in the heart in
mice. Of importance, the circulating levels of human omentin
derived from adipose tissue of mice are similar to the levels
observed in healthy human subjects (8,10). Furthermore,
human omentin at the physiological concentration was
effective in reducing myocyte apoptosis in vitro. Taken
together, these data suggest that human omentin acts as a
crucial adipokine that exerts beneﬁcial actions on the injured
myocardium and that decreased levels of circulating omentin
under conditions of obesity contribute to the exacerbation of
ischemic injury in the heart.
Study limitations. In our clinical study, the sample size was
small. Future studies in a larger population will be required
to elucidate the relationship of circulating omentin levels
with clinical outcomes after AMI.
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2732Conclusions
We found that omentin can protect cardiac myocytes from
apoptosis during I/R through both AMPK- and Akt-
dependent mechanisms, thereby leading to protection
against acute cardiac injury. We also demonstrated the
effectiveness of 1-shot administration of human omentin for
myocardial damage in response to ischemia in a murine
model, indicating the potential clinical utility of omentin.
We and other groups have previously demonstrated that
circulating omentin levels are reduced in patients with cor-
onary heart diseases, including AMI and angina pectoris
(12–14,41). Collectively, these data suggest that omentin
represents a novel target molecule for the prevention and/or
treatment of ischemic heart disease.
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APPENDIX
For an expanded Methods section, as well as supplemental ﬁgures and
a table, please see the online version of this article.
